Drug General Information (ID: DDIQTNEFJ7)
Drug Name			Pramipexole		Drug Info		Levodopa		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiparkinson Agents				Dopaminergic Antiparkinsonism Agents
Structure

Mechanism of Pramipexole-Levodopa Interaction (Severity Level: Moderate)
Additive dopaminergic effects Click to Show/Hide Mechanism Graph
Drug Name		Pramipexole				Levodopa
Mechanism		Dopaminergic effects Dopamine receptor  Agonist				Dopaminergic effects Dopamine receptor  Agonist
Key Mechanism Factor 1
		Factor Name		Dopamine receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.     Click to Show/Hide
Mechanism Description		Additive dopaminergic effects by the combination of Pramipexole and Levodopa

Recommended Action
Management		A reduction of levodopa dosage should be considered during coadministration with pramipexole. In a controlled study in advanced Parkinson's disease, the dosage of levodopa was reduced by an average of 27% from baseline.

References
1	Kompoliti K, Adler CH, Raman R, et al. "Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics." Neurology 58 (2002): 1418-22. [PMID: 12011296]
2	Product Information. Mirapex (pramipexole). Boehringer Ingelheim, Ridgefield, CT.